P orcine endothelial cells in culture produce a vasoconstrictor peptide that has been named endothelin (ET). 1 ET, a 21-amino acid peptide with two disulfide bridges, is the most potent vasoconstrictor known to date. 1 The porcine and human preproendothelin genes have been cloned and shown to be highly homologous and code for the same 21-amino acid peptide. 2 This ET gene appears to be located in chromosome 6. 3 The nucleotide sequence using a rat DNA library predicted a 2 1 -amino acid ET that differed from the porcine or human in six amino acids. 4 Three distinct human endothelin-related genes have been identified in a human genomic DNA library encoding for "classical" endothelin (ET-1), "rat" endothelin (ET-3), and a new ET (ET-2) that differs in two amino acids from ET-1. 5 An additional ET molecule, identified from a mouse genomic DNA with a structure that differs in two amino acids from ET-2, was predicted from the nucleotide sequence of a mouse complementary DNA (cDNA) library and called vasoactive intestinal contractor. 6 The venom of the Israeli Burrowing Asp, Atractaspis engaddensis, contains a group of 21-residue isocardiotoxic peptides called sarafotoxins that show homology in structure and function with ET. 7 High-affinity, specific ET receptors have been described in the adrenal gland. 8 Autoradiography using [
125 I]ET-1 shows preferential localization of binding to the zona glomeniiosa 9 with a distribution pattern very similar to that of atrial natriuretic factor. 10 ET-1 stimulated aldosterone production when incubated with cultured calf 8 or freshly dispersed rabbit 11 zona glomeniiosa cells; however, it was less potent than angiotensin II (Ang II). Sarafotoxin S6b (S6b) is equipotent with ET-1 in displacing [
125 I]ET-1 from its receptor in cardiac membrane fragments, 12 but the hierarchy of potency is highly dependent on the system studied. 13 In this paper, we report the presence of receptor heterogeneity and stimulation of aldosterone secretion by other ETs and S6b in cultured zona glomeniiosa cells.
Gomez-Sanchez el al Endothelin Receptor Subtypes
International (Louisville, Kentucky). Protein concentration was measured using the BCA Protein Assay Reagent Kit (Pierce Chemical Co., Rockford, Illinois).
Iodination of Endothelin-1, Endothelin-3, and Sarafotoxin S6b
The iodination with 125 I and high-performance liquid chromatography purification was done as previously described. 8 
Culture of Adrenal Zona Glomerulosa Cells
Calf adrenal zona glomerulosa cells were cultured in six-or 24-well plates as previously described. 8 The protein concentration was 26.6±0.4 jig/well (mean± SEM, H = 3 2 ) . Cells were plated at a concentration of 200,000 cells/well, and at confluence, there were 438,000±8,300 cells/well (mean±SEM, n = 12).
Binding of [ m I]Endothelin-l, [ I25 I]Endothelin-3, and [ l25 1]Sarafotoxin to Adrenal Cells
The binding of the iodinated peptides to calf zona glomerulosa cells was done as previously described. 8 
Incubation of Adrenal Zona Glomerulosa Cells With Endothelins and Sarafotoxin
Cells grown for 3-4 days in 24-well plates were incubated with increasing concentrations of ETs and S6b for 2 hours at 37° C in.a 5% CO 2 atmosphere. Control incubations with 10~9 M Ang II were also done. Aldosterone secretion was measured by direct radioimmunoassay with a monoclonal antibody. 14 Statistical analysis of the differences between groups was done by analysis of variance using STATVIEW 512 + Program (Brain Power, Calabazas, California) for the Macintosh computer.
Down-regulation of Endothelin-1 and Sarafotoxin S6b Receptors
Cells were incubated for 2 hours with 1 nM peptide, washed three times with Hanks' balanced salt solution, incubated 2 hours with Ham F-12 containing 0.2% bovine serum albumin, and washed, and then receptors were measured as previously described. B rau was measured using a Scatchard plot. To be certain that these washing conditions eliminated all bound peptide before measuring receptor number, cells were incubated under identical conditions with [ 125 I]ET-1, and the amount of radioactivity was measured after washing. Less than 5% of bound counts remained after the washing procedure. 
LOG MOLAR CONCENTRATION FIGURE 2. Plotting showing displacement of [ 125 I]endothelin-l (ET-1) by unlabeled endothelins (ET-1, ET-2, and ET-3) and Sarafotoxin S6b (S6b) from the adrenal receptors.

I] Sarafotoxin S6b (125I-S6b) by unlabeled Sarafotoxin S6b (S6b) and endothelins (ET-1, ET-2, and ET-3) front the adrenal receptors.
and S6b receptors to the same extent (Table 1 ). This finding is in agreement with the displacement studies that suggested that ET-1 and ET-2 bind to the same site or sites. In cells pretreated with ET-3, the ET-1 receptors were not affected nor surprisingly were the S6b receptors because ET-3 displaced S6b so well.
Pretreatment with unlabeled S6b decreased the ET-1 binding by 28% and S6b binding by 40%. These results are in agreement with the hypothesis of one shared receptor for ET-1 and S6b, which is downregulated by both, and another receptor for ET-1, which is not affected by S6b pretreatment but down-regulated by ET-1 and to which S6b preferentially binds.
Effect of Endothelin-1 and Sarafotoxin S6b on Aldosterone Production
ET-1 and S6b stimulated aldosterone secretion to a similar degree (Figure 4 ).
Discussion
We have previously shown and further confirmed that the ETs bind to adrenal receptors and are capable of stimulating aldosterone secretion but with a significant lesser potency than Ang II. 8 The highly homologous snake venom S6b was also capable of stimulating aldosterone secretion with a potency similar to ET-1. ET-1 and S6b were equal in their ability to stimulate aldosterone secretion; however, S6b displaced [ There is no evidence to indicate that S6b exists in mammals; however, its strong structural homology makes it a useful investigative tool. These studies suggest that there are two ET-1 receptors, but because of the high affinity of ET-1 for both receptors, the Scatchard plot using [ 125 I]ET-1 studies was unable to give enough resolution to suggest the presence of a second receptor. The high-affinity receptor (B mai of 8 fmol/well and K4 of 0.05 nM) we call the ET-la receptor, and the previously described receptor 8 ( B^ of 36 fmol/ well [actually 36-8 fmol/well]) w e are calling the ET-1J3. S6b served as a tool to uncover the existence of the first receptor.
Further evidence that these are two different receptors is that down-regulation of the receptors is different according to which peptide is used for its induction. S6b preferentially down-regulates the higher affinity, lower capacity, ET-la receptor, and ET-1 or ET-2 best down-regulates the previously described ET-1/3 receptor. 8 It is interesting that ET-3 competes very poorly with [ I]S6b for binding. ET-3 is a very poor stimulator of aldosterone secretion. 8 This pattern of competitive binding behavior would disagree with the postulate that the stimulation of aldosterone secretion is through its interaction with the high-affinity ET-la receptor because ET-3 is slightly more potent than ET-1 for binding to this receptor. It is very likely that the binding of ET-3 to the S6b-preferring receptor results in the formation of a peptide-receptor complex that does not activate the mediators of stimulation. Further evidence for this hypothesis is provided by the inability of ET-3 to induce downregulation of either receptor (Table 1 ). There is the possibility (that was not tested) that ET-3 might have properties antagonistic to the other ETs.
Receptor heterogeneity for ETs has been described for other tissues. Chick cardiac membranes exhibit two types of receptors, one ET-l,2-preferring receptor that exhibits an order of potency of ET-2^ET-1>ET-3>S6b and a second type, or ET-3-preferring receptor, that exhibits an order of potency of ET-3>ET-2>ET-l£S6b. 16 In the order of S6b potency, these receptors are different from those described in the adrenal gland. Kloog et al 13 described three apparent receptor subtypes, that is, a high-affinity ET-1/S6b subtype of smooth muscle, a high-affinity S6c subtype typical of the cerebellum, and a less selective subtype typical of the caudate putamen that binds all these peptides with high affinity. It is apparent that there is a great heterogeneity in receptor subtypes; however, the significance is not clear because only ET-1 has been isolated from tissue. The structures of other ETs have been determined by using the nucleotide sequence of cDNAs isolated with a probe against ET-1, 4 -6 and it is not known if and where gene expression for these peptides occurs.
ET-1 action in the adrenal is likely to be caused by an increased secretion at a paracrine site because circulating amounts of ET-1 are very small. 17 Malignant hypertension is associated with an increased secretion of aldosterone in a significant number of cases. 18 On treatment, the aldosterone secretion normalizes much later than the renin-angiotensin system, the main stimulator of aldosterone secretion, suggesting the action of an additional aldosterone stimulator or stimulators, 18 one of which might be ET-1. Significant endothelial changes and damage occur in malignant hypertension, which might lead to increased secretion of ET-1. 119 The role of ET-1 in the acceleration of the disease process in malignant hypertension is speculative at this time, but if ET-1 does have a role, then aldosterone overproduction induced by ET-1 is a reasonable hypothesis.
